AI Image
GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug
NewsNation • • business
Key Points:
- Lawsuits against GLP-1 drugmakers Eli Lilly and Novo Nordisk allege their weight-loss drugs cause permanent eye damage, specifically non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to blindness.
- Todd Engel, a patient who took Ozempic for diabetes, claims he lost vision in both eyes and is now legally blind, asserting he was not warned about the potential risk of NAION.
- Engel’s attorney argues that studies show GLP-1 drugs are an independent risk factor for NAION, and drugmakers should be responsible for including warnings on U.S. labels.
- NAION warnings are present on drug labels in Canada, Europe, and Australia, but not currently on U.S. labels for Ozempic, Wegovy, and Zepbound; the FDA is reviewing the potential link but has not made a determination.
- The lawsuits highlight concerns about patient safety and the need for transparent risk communication regarding GLP-1 medications.
